Lexicon Pharmaceuticals, Inc.
NASDAQ:LXRXBiotechnology
-$0.05 today
- Market cap
- $765.80M
- Beta
- 1.07
- P/E (TTM)
- -30.5
- EPS (TTM)
- -$0.07
Volume 2.02M
Average 2.48M
LXRX Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Lexicon Pharmaceuticals, Inc.NASDAQ: LXRX
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity rises 64.9% from a year ago
Total equity stood at $202.86M at the end of Q1 FY2026, up 64.9% from a year earlier and up 88.6% from the prior quarter. Over 3 fiscal years it compounded at -2.8% a year.
Context
- Total equity amounted to 75.5% of total assets at the end of Q1 FY2026, up 34.1 pp from a year earlier.
- Total equity increased in 1 of the last 3 fiscal years.
What to watch
Whether total equity keeps rising in the next quarterly balance sheet after a +64.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 107.54M USD
- Year-over-year change
- -26.3%
- 4-year CAGR
- -1.4%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 107.54M | -26.3% |
| FY2024 | 2024-12-31 | 145.95M | +56.8% |
| FY2023 | 2023-12-31 | 93.11M | -20.5% |
| FY2022 | 2022-12-31 | 117.12M | +3.1% |
| FY2021 | 2021-12-31 | 113.6M | — |
Total Equity vs competitors
How LXRX compares with its peers on the latest reported figures
- LXRX's Mar 2026 total equity of $202.86M is the 5th highest of the 11 companies compared; the peer median is $134.47M.
- Its year-over-year change of +64.9% is the 4th highest of 11, against a peer median of +29.5%.
- Total equity amounts to 75.5% of total assets for LXRX, versus a peer median of 80.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $415.56M | +89.1% | +20.0% | 95.1% | |
| Mar 2026 | $399.9M | +2053.8% | — | 79.2% | |
| Sep 2026 | $393.64M | -36.3% | -5.1% | 13.5% | |
| Sep 2026 | $302.76M | +59.5% | +19.5% | 97.4% | |
| Mar 2026 | $202.86M | +64.9% | -2.8% | 75.5% | |
| Mar 2026 | $198.27M | +234.5% | -0.4% | 87.9% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $70.68M | -69.0% | — | 45.9% |
| Mar 2026 | $47.24M | +39.1% | +20.8% | 89.0% | |
| Mar 2026 | -$59.2M | -1.0% | — | 8.0% | |
| Jun 2026 | -$165.36M | +19.9% | — | 5.1% | |
| Jun 2026 | -$454.29M | -7.8% | — | 81.4% | |
| Peer median (excluding LXRX) | $134.47M | +29.5% | +19.5% | 80.3% | |
Competitors are the stored peer set for LXRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 64.07M | 46.35M | 22.47M | 66.66M | 34.33M |
| Short-term Investments | 22.68M | 92.01M | 147.56M | 171.3M | 61.9M |
| Net Receivables | 14K | 28K | 1.01M | 3.47M | 2.38M |
| Inventory | 0 | 0 | 381K | 231K | 281K |
| Other Current Assets | 0 | 2.48M | 5.13M | 4.53M | 3M |
| Total Current Assets | 88.92M | 140.87M | 176.55M | 246.19M | 101.9M |
| Property, Plant & Equipment (Net) | 3.45M | 8.48M | 7.51M | 7.32M | 9.18M |
| Goodwill | 44.54M | 44.54M | 44.54M | 44.54M | 44.54M |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 412K | 828K | 368K | 29.37M |
| Total Non-current Assets | 47.99M | 53.43M | 52.88M | 52.23M | 83.09M |
| Total Assets | 136.91M | 194.3M | 229.43M | 298.42M | 184.99M |
| Account Payables | 9.15M | 10.4M | 14.39M | 14.8M | 3.08M |
| Short-term Debt | 0 | 0 | 0 | 0 | 6.24M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 5.71M | 3.66M | 9.59M | 14.71M | 5.13M |
| Total Current Liabilities | 22.12M | 23.17M | 31.55M | 45.25M | 20.87M |
| Long-term Debt | 0 | 48.58M | 99.51M | 100.3M | 49.41M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 582K |
| Total Non-current Liabilities | 1.19M | 54M | 104.77M | 107.22M | 56.58M |
| Total Liabilities | 23.31M | 77.18M | 136.32M | 152.47M | 77.45M |
| Common Stock | 150K | 189K | 245K | 363K | 366K |
| Retained Earnings | (1.49B) | (1.59B) | (1.77B) | (1.97B) | (2.02B) |
| Accumulated OCI | (10K) | (428K) | 31K | 119K | 30K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 113.6M | 117.12M | 93.11M | 145.95M | 107.54M |
| Total Debt | 2.28M | 55.29M | 106.06M | 108.4M | 62.24M |
| Net Debt | (61.79M) | 8.95M | 83.6M | 41.74M | 27.91M |
Lexicon Pharmaceuticals, Inc.
NASDAQ:LXRX
Intrinsic Alpha fair value
Locked
Current Price
$1.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.